| dc.contributor.author | Alkan, Ali | |
| dc.contributor.author | Yaşar, Arzu | |
| dc.contributor.author | Toprak, Serhat | |
| dc.date.accessioned | 2020-11-20T14:40:23Z | |
| dc.date.available | 2020-11-20T14:40:23Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1078-1552 | |
| dc.identifier.issn | 1477-092X | |
| dc.identifier.uri | https://doi.org/10.1177/1078155219835592 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12809/729 | |
| dc.description | Yasar, Hatime/0000-0002-0545-1383 | en_US |
| dc.description | WOS: 000501268400028 | en_US |
| dc.description | PubMed ID: 30854926 | en_US |
| dc.description.abstract | Kaposi sarcoma (KS) is a low-grade mesenchymal angioproliferative disease, mostly observed in immune compromised patients. KS is mostly encountered in HIV-positive or organ transplant patients. The drugs causing immunosuppression have also been associated with KS. Here, we present a KS experience associated with rituximab-based therapy. | en_US |
| dc.item-language.iso | eng | en_US |
| dc.publisher | Sage Publications Ltd | en_US |
| dc.item-rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Rituximab | en_US |
| dc.subject | Kaposi Sarcoma | en_US |
| dc.subject | Lymphoma | en_US |
| dc.subject | HHV-8 | en_US |
| dc.title | Kaposi sarcoma associated with rituximab-based cytotoxic therapy | en_US |
| dc.item-type | article | en_US |
| dc.contributor.department | MÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
| dc.identifier.doi | 10.1177/1078155219835592 | |
| dc.identifier.volume | 26 | en_US |
| dc.identifier.issue | 1 | en_US |
| dc.identifier.startpage | 220 | en_US |
| dc.identifier.endpage | 223 | en_US |
| dc.relation.journal | Journal of Oncology Pharmacy Practice | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
